Potential efficacy of natural Cyclic Glycine-Proline (cGP) supplementation in reducing the risk of developing metabolic syndrome
Body composition, organ fat, metabolism and insulin sensitivity
This is an open label trial, aiming to evaluate the efficacy of natural cGP in supporting metabolism by measuring body composition, lipid profiles, insulin resistance and organ fats. The protocol has been approved by the Medical Ethics Committee of Tian-you Hospital, affiliated with Wuhan University of Science and Technology (TY-IEC2026-035). The trial consists of three hospital visits spaced three months apart. Participants will be instructed to continue any prescribed medications for existing medical conditions and to maintain their usual lifestyle throughout the trial period. Following the first hospital visit, participants will begin supplementation with capsules containing natural cGP for six months. The capsules are dispensed monthly, and participants’ self-reported symptoms and general health will be monitored through monthly clinical visits or scheduled phone calls. The active ingredient contains standardized physiological concentrations of natural cGP, derived from New Zealand dietary sources. All capsules will be manufactured in a GMP-certified facility in New Zealand. Each capsule weighs 500 mg and provided 40-45 µg of natural cGP.
1. The study includes male and female participants aged 35–60 years 2. Participants have no medical history of metabolic syndrome 3. Participants are classified as overweight based on body fat percentage measured by dual-energy X-ray absorptiometry (DXA) 3.1. Body fat percentage exceeds 37 percent in women 3.2. Body fat percentage exceeds 25 percent in men 4. Organ fat volume is greater than 12 percent of total body fat 5. Recruitment is independent of plasma lipid profiles 6. Recruitment is independent of fatty liver diagnosis 7. Recruitment is independent of plasma insulin concentrations
1. Participants will be excluded if they have any form of diabetes 2. Participants will be excluded if they have hypertension, defined as blood pressure greater than 130/90 mmHg 3. Participants will be excluded if they are taking any medications for diabetes, hypertension, or weight management 4. Additional exclusion criteria include a medical history of degenerative neurological conditions 5. Additional exclusion criteria include cognitive impairment 6. Additional exclusion criteria include major mental health disorders: 6.1. Schizophrenia 6.2. Severe depression 6.3. Anxiety